Key result
Continuous rivaroxaban is linked to similar minor bleeding rates versus a warfarin switch in mild PE.
Why the study?
Novel oral anticoagulants like rivaroxaban offer advantages over conventional anticoagulants such as warfarin, but their role in managing venous thromboembolism in Egyptian patients needed evaluation.
Does oral rivaroxaban for 6 months compared to rivaroxaban for 1 week followed by warfarin for 6 months improve safety in patients with mild pulmonary embolism?
Observational (n=120)
Does oral rivaroxaban for 6 months compared to rivaroxaban for 1 week followed by warfarin for 6 months improve safety in patients with mild pulmonary embolism?
Rivaroxaban is a safe and suitable alternative to warfarin for the management of mild venous thromboembolism, offering comparable safety without the need for routine monitoring.
Answers are grounded in this paper and cite their sources.
Supports rivaroxaban continuation without monitoring in mild PE; leaves open randomized confirmation of safety equivalence.
Over 50 years the research work all over the world was concerning to find out a novel oral heparin to avoid the side effects of conventional anticoagulants as warfarin which requires changes in diet and lifestyle, regular checkup, and has a risk of severe hemorrhage. Rivaroxaban offers such advantages as oral mode of administration, more predictable anticoagulant response, greater specificity with no need for routine checkup and patient monitoring and has a uniform dose. When switching patients from warfarin to rivaroxaban, warfarin is discontinued and rivaroxaban is started as soon as INR is below 3.0 to avoid periods of inadequate anticoagulation. To study the role and suitability of oral rivaroxaban therapy in management of venous thromboembolism in Egyptian patients. This work was done over 120 mild or minor pulmonary embolism patients, divided into 2 groups, group I included 100 patients received oral rivaroxaban for 1 week, continued with warfarin for 6 months guided with INR measurement, group II included 20 patients who are financially supported and can continue with rivaroxaban for 6 months. The following was done for all patients. Clotting time (CT), D Dimer, INR, APTT, platelet count, complete liver and kidney functions, digital X ray Chest, multi-slice CT angiogram in some cases, and ECG, CK MB and troponin when needed. Our patients were divided into 2 groups, group I included 100 patients 54 males and 46 females with a mean age of 48.3 ± 15.43 and a mean body weight of 84.7 ± 16.4 group II included 20 patients 11 males and 9 females with a mean age of 45.6 ± 12.21and a mean body weight of 85.2 ± 12, the recorded side effects were minor bleeding in 11% of the cases of group I and 10% of the cases of group II, headache in 6% of the cases of group I and 5% of the cases of group II, GIT upset in 5% of the cases in both groups, dizziness in 4% of the cases of group I and 5% of the cases of group II with no statistical significant differences between the 2 arms of the study. Rivaroxaban is a rapid onset of anticoagulant that can be given in fixed doses without routine monitoring. It can replace injectable anticoagulants as an initial treatment in management of patients with mild venous thromboembolism as it is suitable as regard the economic and the health status of the Egyptian patients.
No takes yet. Share an insight, caveat, or question.
Abdalwahab et al. (2015) conducted an observational in mild or minor pulmonary embolism (n=120). Rivaroxaban vs. Rivaroxaban for 1 week followed by warfarin was evaluated on Minor bleeding (p=not significant). Continuous rivaroxaban for 6 months resulted in similar rates of minor bleeding compared to switching to warfarin after 1 week in patients with mild pulmonary embolism.
Synapse has enriched 10 related papers. Consider them for comparative context: